Taysha Gene Therapies Q3 EPS $(0.64) Beats $(0.82) Estimate_老虎社区_美港股上老虎

Taysha Gene Therapies Q3 EPS $(0.64) Beats $(0.82) Estimate

Benzinga2022-11-08

Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.82) by 21.95 percent. This is a 52.59 percent increase over losses of $(1.35) per share from the same period last year.

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

GWPAN
·2023-03-22
应该是decrease 52%
回复
点赞
举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2281799578?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2022-11-08 21:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2281799578","market":"us","top_or_hot":-1,"title":"Taysha Gene Therapies Q3 EPS $(0.64) Beats $(0.82) Estimate","media":"Benzinga","content":"<html><body><p>Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.82) by 21.95 percent. This is a 52.59 percent increase over losses of $(1.35) per share from the same period last year.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Taysha Gene Therapies Q3 EPS $(0.64) Beats $(0.82) Estimate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTaysha Gene Therapies Q3 EPS $(0.64) Beats $(0.82) Estimate\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-11-08 21:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/earnings/22/11/29611928/taysha-gene-therapies-q3-eps-0-64-beats-0-82-estimate><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.82) by 21.95 percent. This is a 52.59 percent increase over losses ...</p>\n\n<a href=\"https://www.benzinga.com/news/earnings/22/11/29611928/taysha-gene-therapies-q3-eps-0-64-beats-0-82-estimate\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TSHA","symbol_name":"Taysha Gene Therapies, Inc.","start_time":0,"source_url":"https://www.benzinga.com/news/earnings/22/11/29611928/taysha-gene-therapies-q3-eps-0-64-beats-0-82-estimate","article_id":"2281799578","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2281799578","pubTimestamp":1667912823,"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.82) by 21.95 percent. This is a 52.59 percent increase over losses of $(1.35) per share","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"TSHA":"Taysha Gene Therapies, Inc."},"translate_title":"Taysha Gene Therapies第三季度每股收益（0.64）超过（0.82）预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TSHA":1},"content_text":"Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.82) by 21.95 percent. This is a 52.59 percent increase over losses of $(1.35) per share from the same period last year.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[{"id":650416347,"gmtCreate":1679448425189,"gmtModify":1679448426732,"author":{"id":"4101979677494340","authorId":"4101979677494340","name":"GWPAN","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"应该是decrease 52%","listText":"应该是decrease 52%","text":"应该是decrease 52%","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/650416347","repostId":2281799578,"repostType":2,"repost":{"id":"2281799578","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1667912823,"share":"https://www.laohu8.com/m/news/2281799578?lang=&edition=full","pubTime":"2022-11-08 21:07","market":"us","language":"en","title":"Taysha Gene Therapies Q3 EPS $(0.64) Beats $(0.82) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2281799578","media":"Benzinga","summary":"Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.82) by 21.95 percent. This is a 52.59 percent increase over losses of $(1.35) per share","content":"<html><body><p>Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.82) by 21.95 percent. This is a 52.59 percent increase over losses of $(1.35) per share from the same period last year.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Taysha Gene Therapies Q3 EPS $(0.64) Beats $(0.82) Estimate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTaysha Gene Therapies Q3 EPS $(0.64) Beats $(0.82) Estimate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2022-11-08 21:07</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.82) by 21.95 percent. This is a 52.59 percent increase over losses of $(1.35) per share from the same period last year.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSHA":"Taysha Gene Therapies, Inc."},"source_url":"https://www.benzinga.com/news/earnings/22/11/29611928/taysha-gene-therapies-q3-eps-0-64-beats-0-82-estimate","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2281799578","content_text":"Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.82) by 21.95 percent. This is a 52.59 percent increase over losses of $(1.35) per share from the same period last year.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}